Teva Pharmaceutical Industries (TEVA) – aksjekurser og nyheter

Symboler Symboler	Pris	Endring	Endring (%)	Trend	Forrige pris ved stengetid	Åpne	Høy	Lav	Volum	Markedsverdi
SIXB Materials SIXB Materials	SIXB −0,32%	1 100,57	−3,53	−0,32%	—	1 104,10	1 103,92	1 108,75	1 097,16	—	—
SIXC Communications SIXC Communications	SIXC +0,16%	605,15	+0,99	+0,16%	—	604,16	604,16	610,19	604,12	—	—
SIXE Energy SIXE Energy	SIXE −0,22%	1 195,19	−2,62	−0,22%	—	1 197,81	1 200,58	1 213,07	1 192,02	—	—
SIXI Industrials SIXI Industrials	SIXI −0,03%	1 739,91	−0,50	−0,03%	—	1 740,41	1 739,55	1 750,27	1 730,60	—	—
SIXM Financials SIXM Financials	SIXM +0,65%	638,56	+4,12	+0,65%	—	634,44	633,13	639,87	633,01	—	—
SIXR Staples SIXR Staples	SIXR −1,11%	831,57	−9,33	−1,11%	—	840,90	839,53	841,73	831,10	—	—
SIXRE Real estate SIXRE Real estate	SIXRE −0,82%	213,36	−1,77	−0,82%	—	215,13	215,13	215,85	213,24	—	—
SIXT Technology SIXT Technology	SIXT +0,17%	3 234,18	+5,47	+0,17%	—	3 228,71	3 225,62	3 235,43	3 198,95	—	—
SIXU Utilities SIXU Utilities	SIXU −0,02%	935,65	−0,22	−0,02%	—	935,87	938,37	942,00	935,65	—	—
SIXV Health care SIXV Health care	SIXV −0,54%	1 449,26	−7,86	−0,54%	—	1 457,12	1 452,74	1 466,88	1 449,18	—	—
SIXY Discretionary SIXY Discretionary	SIXY −0,72%	2 382,45	−17,39	−0,72%	—	2 399,84	2 389,71	2 394,61	2 371,22	—	—

Inntekt Q1 2026 • om 1 dag

Se detaljene

TEVA:NYSE

Teva Pharmaceutical Industries

31,26 USD

+2,02%

(+0,62) 1 D

31,24 USD

−0,06% (−0,020)

Før børsåpning

Stengt: 27. apr., 16:00:05 GMT-4 · USD

Alle symboler

1 D

5 D

1 M

6 M

I år

1 Å

5 Å

MAKS

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for TEVA …

Åpne

30,65 USD

Høy

31,66 USD

Lav

30,58 USD

Markedsverdi

36,68 mrd.

Snittvolum

5,95 mill.

Volum

5,31k

P/E-forhold

25,78

52 u høy

37,34 USD

52 u lav

14,16 USD

EPS

1,21 USD

Beta

0,76

Utestående aksjer

1,16 mrd.

Antall ansatte

32k

Relaterte aksjer

Woodward, Inc.Common Stock

366,63 USD

+0,46%

Nyhetssaker

Fra kilder på nettet

NAI500

for 5 timer siden

Teva Pharmaceuticals to Release Quarterly Report, Analysts Suggest Waiting for Post-Earnings Purchase

Gotrade

for 7 timer siden

Pharma Stock Picks: Teva, Novo Nordisk, Eli Lilly in Focus

The Motley Fool

for 8 timer siden

Teva Pharmaceutical's Turnaround Is Working. Here's When to Buy the Stock.

MarketBeat

for 3 døgn siden

Teacher Retirement System of Texas Cuts Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Profil

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America. Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. Wikipedia

Om Teva Pharmaceutical Industries

Administrerende direktørRichard Francis

Ansatte32k

Grunnlagt13. feb. 1944

Hovedkontor-

Sektor-

Nettstedteva.co.il

Alle verdier i USD	mars 2025	juni 2025	sep. 2025	des. 2025
Inntekt	3,89 mrd.	4,18 mrd.	4,48 mrd.	4,71 mrd.
Varekostnad	2,01 mrd.	2,07 mrd.	2,18 mrd.	2,06 mrd.
Direkte driftskostnader	2,01 mrd.	2,07 mrd.	2,18 mrd.	2,06 mrd.
Utgifter til forskning og utvikling	247,00 mill.	244,00 mill.	256,00 mill.	267,00 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	919,00 mill.	959,00 mill.	973,00 mill.	1,12 mrd.
Driftskostnader	1,17 mrd.	1,21 mrd.	1,24 mrd.	1,37 mrd.
Totale driftskostnader	3,18 mrd.	3,28 mrd.	3,41 mrd.	3,43 mrd.
Driftsinntekter	709,00 mill.	894,00 mill.	1,07 mrd.	1,28 mrd.
Andre ikke-operasjonelle inntekter	47,00 mill.	−90,00 mill.	−27,00 mill.	-
EBT inkludert uvanlige elementer	294,00 mill.	204,00 mill.	648,00 mill.	90,00 mill.
EBT uten uvanlige elementer	482,00 mill.	643,00 mill.	832,00 mill.	1,08 mrd.
Kostnad for inntektsskatt	74,00 mill.	−78,00 mill.	214,00 mill.	−390,00 mill.
Faktisk avgiftssats	25,17 %	−38,24 %	33,02 %	−433,33 %
Andre driftskostnader	2,00 mill.	5,00 mill.	9,00 mill.	−17,00 mill.
Nettoinntekt	214,00 mill.	282,00 mill.	433,00 mill.	480,00 mill.
Netto fortjenestemargin	5,50 %	6,75 %	9,67 %	10,19 %
Resultat per aksje	0,52	0,66	0,78	0,96
Rente- og investeringsinntekter	-	-	-	92,00 mill.
Rentekostnader	−212,00 mill.	−220,00 mill.	−205,00 mill.	−280,00 mill.
Netto rentekostnader	−212,00 mill.	−220,00 mill.	−205,00 mill.	−188,00 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	953,00 mill.	1,14 mrd.	1,32 mrd.	1,54 mrd.
Gevinst eller tap ved salg av eiendeler	-	−2,00 mill.	-	-

AI-innhold kan inneholde feil. Finn ut mer

HjelpSend tilbakemeldingPersonvern Vilkår Ansvarsfraskrivelse

Finance

Utforskning